v3.25.2
Segments - Reconciliation of Revenue and Adjusted EBITDA to Net Loss (Details) - USD ($)
$ in Thousands
3 Months Ended 6 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Jun. 30, 2025
Jun. 30, 2024
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue $ 47,397 $ 69,423 $ 94,247 $ 133,602
Cost of revenue 39,629 38,582 78,754 76,917
Research and development 4,882 4,924 9,770 9,956
Amortization (7,200) (6,869) (14,230) (13,738)
Depreciation (5,957) (5,556) (11,650) (10,342)
Interest expense (6,815) (11,939) (13,593) (22,803)
Interest income 3,030 7,086 6,255 14,296
Corporate costs, net of eliminations (14,000) (13,829) (28,320) (30,048)
Other adjustments:        
Acquisition contingent consideration (140) 1,195 (140) 1,195
Acquisition integration costs (831) (1,224) (1,598) (3,722)
Stock-based compensation (6,789) (13,763) (17,192) (25,820)
Merger and acquisition related expenses (92)   (1,270) (30)
Acquisition related tax adjustment (4,153) (2,554) (4,082) (2,441)
Executive leadership transition costs (2,007)   (2,007)  
Goodwill impairment (30,449) 0 (42,884) 0
Property and equipment impairment (1,052)   (1,052)  
Restructuring costs   8   (11)
Other (1,260) (228) (2,414) (632)
Loss before income taxes (74,125) (20,855) (126,816) (43,264)
Income tax expense (benefit) 4,288 2,435 4,126 2,164
Net loss (69,837) (18,420) (122,690) (41,100)
Stock-based compensation benefit related to forfeited stock with executive leadership 3,300   3,300  
Restructuring related compensation benefit included in equity based compensation   0   1,200
Nucleic Acid Production        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 31,085 54,586 59,835 100,602
Other adjustments:        
Goodwill impairment     (42,884)  
Biologics Safety Testing        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 16,312 14,837 34,412 33,000
Other adjustments:        
Goodwill impairment     0  
Operating Segments        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 47,397 69,423 94,247 133,602
Adjusted EBITDA 3,590 26,818 7,361 50,832
Operating Segments | Nucleic Acid Production        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 31,085 54,586 59,835 100,602
Cost of revenue 24,407 23,854 49,229 48,478
Selling and marketing 6,367 5,728 12,135 10,121
General and administrative 5,179 4,886 9,694 9,327
Research and development 2,496 2,658 4,994 5,121
Other segment items (94) 7 (47) 14
Adjusted EBITDA (7,270) 17,453 (16,170) 27,541
Operating Segments | Biologics Safety Testing        
Segment Reporting, Revenue Reconciling Item [Line Items]        
Revenue 16,312 14,837 34,412 33,000
Cost of revenue 3,002 3,102 5,803 4,856
Selling and marketing 745 702 1,575 1,379
General and administrative 1,186 1,158 2,399 2,435
Research and development 516 509 1,101 1,038
Other segment items 3 1 3 1
Adjusted EBITDA $ 10,860 $ 9,365 $ 23,531 $ 23,291